ImmunoACT: an IIT Bombay spin-off company, incubated at SINE
Driving India's first CAR-T cell therapy
Full stack company: Research to commercialisation
India ranks second in global cancer mortality
Very high number of patients relapse and/or refractory to conventional therapies: Leukaemia and Lymphoma*
High response rate: CAR-T cells are highly effective compared to chemotherapy, biologics and bone marrow transplant
* Based on inputs from multiple centres in India
Cancer is a disease in which some of the body’s cells grow uncontrollably and spread to other parts of the body.
Cancers are a group of conditions which are marked by significant changes to cells, often genetic in nature, leading to their aberrant and uncontrolled proliferation
Difference Between Cancer and normal cells
What is Cancer?
How Does Cancer Develop?
Type of Cancers
CAR-T : The Intent to Cure Cancer
They are made by collecting T cells from the patient and re-engineering them in the laboratory to produce proteins on their surface called chimeric antigen receptors, or CARs. The CARs recognize and bind to specific proteins, or antigens, on the surface of cancer cells.
Recoveries are the strongest motivation
Journey of these patients, who, with the unwavering support of their families, fastidious and keen treatment-care by provided by Tata Memorial Hospital, and the cutting-edge treatment of ImmunoACT’s Actaly-cel, have emerged victorious in their battle against cancer.
They are now in remission, and in pursuit of better clinical outcomes. Their stories serve as a beacon of hope and a testament to the power of perseverance, love, and advanced medical treatment.
Stay up-to-date with the latest news and developments from our company with our official newsletter. Each issue is packed with informative articles, exclusive offers, and exciting updates on our products and services. Don’t miss out on the latest happenings